Sustainability Report for 2022
During 2022, significant progress was made to implement and anchor Impilo’s Sustainability Blueprint with our portfolio companies. We always aim to accelerate positive health outcomes through our investments and welcome you to read more about our progress in Impilo’s Sustainability Report 2022
Read the full report here
News
Impilo Closes €320m Single Asset Continuation Fund Transaction to Support the Continued Growth of Immedica Pharma
On 20th September 2024, Impilo, a Nordic healthcare investment firm and KKR, a leading global investment firm, announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm, focused on the commercialization of medicines for rare diseases and specialty care products.
Impilo and KKR Completes Joint Acquisition of Immedica Pharma
Stockholm and London, 19 September 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.